The role of interleukin-6 in the evolution of ovarian cancer: Clinical and prognostic implications - A review

Journal of Molecular Medicine

Volumn 91, Issue 12, 2013, Pages 1355-1368

  Macciò, Antonio ^a   Madeddu, Clelia ^b  

^a Ospedale Oncologico A Businco   (Italy)

^b UNIVERSITY OF CAGLIARI   (Italy)

Author keywords

Anemia; Cachexia; Interleukin 6; Leptin; Ovarian cancer; Quality of life

Indexed keywords

C REACTIVE PROTEIN; CORTICOTROPIN RELEASING FACTOR; CYCLOOXYGENASE 2; GLUCOSE; HEPARIN; HEXOKINASE; HYDROCORTISONE; HYPOXIA INDUCIBLE FACTOR 1; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INSULIN; INTERLEUKIN 6; LACTATE DEHYDROGENASE; LACTIC ACID; LEPTIN; LIPOPROTEIN LIPASE; LOW MOLECULAR WEIGHT HEPARIN; NITRIC OXIDE SYNTHASE; NONESSENTIAL AMINO ACID; PROCOAGULANT; PROTEIN BAK; PROTEIN BAX; PROTEIN P53; PYRUVATE DEHYDROGENASE; PYRUVATE DEHYDROGENASE KINASE; SILTUXIMAB; STAT3 PROTEIN; THIOCTIC ACID; THROMBOPOIETIN; TOLL LIKE RECEPTOR 4; TRIACYLGLYCEROL;

ADIPOCYTE; ADIPOSE TISSUE; ADVANCED CANCER; ANAEROBIC GLYCOLYSIS; ANEMIA; ANOREXIA; ANTICOAGULANT THERAPY; ANTIINFLAMMATORY ACTIVITY; APOPTOSIS; AREA UNDER THE CURVE; ASCITES; AUTOPHAGY; BODY COMPOSITION; BODY WEIGHT; CACHEXIA; CANCER CELL; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER PROGNOSIS; CANCER REGRESSION; CANCER SURVIVAL; CARBOHYDRATE METABOLISM; CD4+ T LYMPHOCYTE; CELL DEATH; CELL GROWTH; CELL PROLIFERATION; CELL STRESS; CELL VIABILITY; CHEMOTHERAPY INDUCED ANEMIA; CHRONIC INFLAMMATION; CITRIC ACID CYCLE; COGNITION; COLONY FORMATION; CYTOKINE RELEASE; CYTOTOXICITY; DEATH; DEPRESSION; DISTRESS SYNDROME; DOWN REGULATION; ENERGY; ENERGY BALANCE; ENERGY EXPENDITURE; ENERGY METABOLISM; ENERGY YIELD; ENZYME PHOSPHORYLATION; ERYTHROID PRECURSOR CELL; ERYTHROPOIESIS; EVOLUTION; EXERCISE; FAT MASS; FATIGUE; FERMENTATION; FOOD DEPRIVATION; FOOD INTAKE; GENE EXPRESSION; GLUCONEOGENESIS; GLUCOSE BLOOD LEVEL; GLUCOSE HOMEOSTASIS; GLUCOSE METABOLISM; GLUCOSE OXIDATION; GLUCOSE TOLERANCE; GLUCOSE UTILIZATION; GLYCOLYSIS; GROWTH DISORDER; HEMOGLOBIN BLOOD LEVEL; HOST RESISTANCE; HUMAN; HYPERCHOLESTEROLEMIA; HYPERTRIGLYCERIDEMIA; HYPOTHALAMUS HYPOPHYSIS ADRENAL SYSTEM; HYPOTHALAMUS NUCLEUS; HYPOXIA; IMMUNE DEFICIENCY; IMMUNE RESPONSE; IMMUNE STATUS; IMMUNITY; IMMUNOCOMPETENT CELL; IMMUNOSUPPRESSIVE TREATMENT; IMMUNOSURVEILLANCE; IN VITRO STUDY; IN VIVO STUDY; INFLAMMATION; INSULIN BLOOD LEVEL; INSULIN RESISTANCE; INSULIN SYNTHESIS; INSULINEMIA; INTERFERON PRODUCTION; IRON METABOLISM; LEAN BODY WEIGHT; LIPID METABOLISM; LIPOGENESIS; LIVER CELL; LYMPHOCYTE; LYMPHOCYTE FUNCTION; MACROPHAGE; METABOLIC STRESS; METASTASIS; MITOCHONDRIAL RESPIRATION; MITOCHONDRION; MONOCYTE; MOOD DISORDER; MORTALITY; MUSCLE CELL; NAUSEA; NEUROTRANSMISSION; NITROGEN BALANCE; NONHUMAN; NUTRITIONAL STATUS; OUTCOME ASSESSMENT; OVARY CARCINOMA; OVERALL SURVIVAL; OXIDATIVE PHOSPHORYLATION; OXYGEN TENSION; PANCREAS ISLET BETA CELL; PATHOGENESIS; PERIODICITY; PERIPHERAL BLOOD MONONUCLEAR CELL; PERITONEAL CAVITY; PLASMA; PRIMARY CULTURE; PROTEIN DEGRADATION; PROTEIN FUNCTION; PROTEIN METABOLISM; PROTEIN PHOSPHORYLATION; PROTEIN SYNTHESIS; QUALITY OF LIFE; RETICULOCYTE; REVIEW; SEPSIS; SIGNAL TRANSDUCTION; SKELETAL MUSCLE; STARVATION; STRESS; T LYMPHOCYTE SUBPOPULATION; TH1 CELL; TH2 CELL; THROMBOCYTE COUNT; THROMBOCYTOSIS; THROMBOEMBOLISM; THROMBOPHILIA; TREATMENT RESPONSE; TUMOR ASSOCIATED LEUKOCYTE; TUMOR CELL; TUMOR ESCAPE; TUMOR GROWTH; TUMOR MICROENVIRONMENT; UPREGULATION; VOMITING; WEIGHT REDUCTION;

ANEMIA; BIOLOGICAL MARKERS; ENDOCRINE SYSTEM; ENERGY METABOLISM; FEMALE; HUMANS; IMMUNE SYSTEM; INTERLEUKIN-6; LEPTIN; NEOPLASMS, GLANDULAR AND EPITHELIAL; OVARIAN NEOPLASMS; PROGNOSIS;

EID: 84890307801     PISSN: 09462716     EISSN: 14321440     Source Type: Journal    
DOI: 10.1007/s00109-013-1080-7     Document Type: Review

References (123)

1. Macciò A, Madeddu C, Massa D, Astara G, Farci D, Melis GB, Mantovani G (2009) Interleukin-6 and leptin as markers of energy metabolic changes in advanced ovarian cancer patients. J Cell Mol Med 13:3951-3959
2. Gadducci A, Cosio S, Fanucchi A, Genazzani AR (2001) Malnutrition and cachexia in ovarian cancer patients: pathophysiology and management. Anticancer Res 21:2941-2497
3. Goff B (2012) Symptoms associated with ovarian cancer. Clin Obstet Gynecol 55:36-42
4. Cravo ML, Glória LM, Claro I (2000) Metabolic responses to tumour disease and progression: tumour-host interaction. Clin Nutr 19:459-465
5. Morrison SD (1971) Partition of energy expenditure between host and tumor. Cancer Res 31:98-107
6. Straub RH, Cutolo M, Buttgereit F, Pongratz G (2010) Energy regulation and neuroendocrine-immune control in chronic inflammatory diseases. J Intern Med 267:543-560
7. Warburg O, Wind F, Negelein E (1926) The metabolism of tumors in the body. J Gen Physiol 8:519-530
8. Fabian C, Koetz L, Favaro E, Indraccolo S, Mueller-Klieser W, Sattler UG (2012) Protein profiles in human ovarian cancer cell lines correspond to their metabolic activity and to metabolic profiles of respective tumor xenografts. FEBS J 279:882-891
9. Maciver NJ, Jacobs SR, Wieman HL, Wofford JA, Coloff JL, Rathmell JC (2008) Glucose metabolism in lymphocytes is a regulated process with significant effects on immune cell function and survival. J Leukoc Biol 84:949-957
10. Halliwell B (2012) Free radicals and antioxidants: updating a personal view. Nutr Rev 70:257-265
11. Kirsch M, De Groot H (2001) NAD(P)H, a directly operating antioxidant? FASEB J 15:1569-1574
12. Scott BC, Aruoma OI, Evans PJ, O'Neill C, Van der Vliet A, Cross CE, Tritschler H, Halliwell B (1994) Lipoic and dihydrolipoic acids as antioxidants. A critical evaluation. Free Radic Res 20:119-133
13. Bennani-Baiti N, Davis MP (2008) Cytokines and cancer anorexia cachexia syndrome. Am J Hosp Palliat Care 25:407-411
14. Macciò A, Lai P, Santona MC, Pagliara L, Melis GB, Mantovani G (1998) High serum levels of soluble IL-2 receptor, cytokines, and C reactive protein correlate with impairment of T cell response in patients with advanced epithelial ovarian cancer. Gynecol Oncol 69:248-252
15. Scambia G, Testa U, Benedetti Panici P, Foti E, Martucci R, Gadducci A, Perillo A, Facchini V, Peschle C, Mancuso S (1995) Prognostic significance of interleukin 6 serum levels in patients with ovarian cancer. Br J Cancer 71:354-356
16. Scambia G, Testa U, Panici PB, Martucci R, Foti E, Petrini M, Amoroso M, Masciullo V, Peschle C, Mancuso S (1994) Interleukin-6 serum levels in patients with gynecological tumors. Int J Cancer 57:318-323
17. Plante M, Rubin SC, Wong GY, Federici MG, Finstad CL, Gastl GA (1994) Interleukin-6 level in serum and ascites as a prognostic factor in patients with epithelial ovarian cancer. Cancer 73:1882-1888
18. Lane D, Matte I, Rancourt C, Piché A (2011) Prognostic significance of IL-6 and IL-8 ascites levels in ovarian cancer patients. BMC Cancer 11:210
19. Van der Zee AG, de Cuyper EM, Limburg PC, de Bruijn HW, Hollema H, Bijzet J, Krans M, de Vries EG (1995) Higher levels of interleukin-6 in cystic fluids from patients with malignant versus benign ovarian tumors correlate with decreased hemoglobin levels and increased platelet counts. Cancer 75:1004-1009
20. Nowak M, Glowacka E, Szpakowski M, Szyllo K, Malinowski A, Kulig A, Tchorzewski H, Wilczynski J (2010) Proinflammatory and immunosuppressive serum, ascites and cyst fluid cytokines in patients with early and advanced ovarian cancer and benign ovarian tumors. Neuro Endocrinol Lett 31:375-383
21. Coward JI, Kulbe H (2012) The role of interleukin-6 in gynaecological malignancies. Cytokine Growth Factor Rev 23:333-342
22. Guo Y, Xu F, Lu T, Duan Z, Zhang Z (2012) Interleukin-6 signaling pathway in targeted therapy for cancer. Cancer Treat Rev 38:904-910
23. Dijkgraaf EM, Welters MJ, Nortier JW, van der Burg SH, Kroep JR (2012) Interleukin-6/interleukin-6 receptor pathway as a new therapy target in epithelial ovarian cancer. Curr Pharm Des 18:3816-3827
24. Heinrich PC, Behrmann I, Haan S, Hermanns HM, Müller-Newen G, Schaper F (2003) Principles of interleukin (IL)-6-type cytokine signalling and its regulation. Biochem J 374:1-20
25. Alberti C, Pinciroli P, Valeri B, Ferri R, Ditto A, Umezawa K, Sensi M, Canevari S, Tomassetti A (2012) Ligand-dependent EGFR activation induces the co-expression of IL-6 and PAI-1 via the NFkB pathway in advanced-stage epithelial ovarian cancer. Oncogene 31:4139-4149
26. Liu J, Yang G, Thompson-Lanza JA, Glassman A, Hayes K, Patterson A, Marquez RT, Auersperg N, Yu Y, Hahn WC et al (2004) A genetically defined model for human ovarian cancer. Cancer Res 64:1655-1663
27. Wang Y, Li L, Guo X, Jin X, Sun W, Zhang X, Xu RC (2012) Interleukin-6 signaling regulates anchorage-independent growth, proliferation, adhesion and invasion in human ovarian cancer cells. Cytokine 59:228-236
28. Rabinovich A, Medina L, Piura B, Segal S, Huleihel M (2007) Regulation of ovarian carcinoma SKOV-3 cell proliferation and secretion of MMPs by autocrine IL-6. Anticancer Res 27:267-272
29. Nilsson MB, Langley RR, Fidler IJ (2005) Interleukin-6, secreted by human ovarian carcinoma cells, is a potent proangiogenic cytokine. Cancer Res 65:10794-10800
30. Coward J, Kulbe H, Chakravarty P, Leader D, Vassileva V, Leinster DA, Thompson R, Schioppa T, Nemeth J, Vermeulen J et al (2011) Interleukin-6 as a therapeutic target in human ovarian cancer. Clin Cancer Res 17:6083-6096
31. Hagemann T, Robinson SC, Thompson RG, Charles K, Kulbe H, Balkwill FR (2007) Ovarian cancer cell-derived migration inhibitory factor enhances tumor growth, progression, and angiogenesis. Mol Cancer Ther 6:1993-2002
32. Berek JS, Chung C, Kaldi K, Watson JM, Knox RM, Martínez-Maza O (1991) Serum interleukin-6 levels correlate with disease status in patients with epithelial ovarian cancer. Am J Obstet Gynecol 164:1038-1042
33. Wang Y, Niu XL, Qu Y, Wu J, Zhu YQ, Sun WJ, Li LZ (2010) Autocrine production of interleukin-6 confers cisplatin and paclitaxel resistance in ovarian cancer cells. Cancer Lett 295:110-123
34. Tempfer C, Zeisler H, Sliutz G, Haeusler G, Hanzal E, Kainz C (1997) Serum evaluation of interleukin-6 in ovarian cancer patients. Gynecol Oncol 66:27-30
35. Yigit R, Figdor CG, Zusterzeel PL, Pots JM, Torensma R, Massuger LF (2011) Cytokine analysis as a tool to understand tumour-host interaction in ovarian cancer. Eur J Cancer 47:1883-1889
36. Mantovani G, Macciò A, Madeddu C, Mura L, Gramignano G, Lusso MR, Mulas C, Mudu MC, Murgia V, Camboni P et al (2002) Quantitative evaluation of oxidative stress, chronic inflammatory indices and leptin in cancer patients: correlation with stage and performance status. Int J Cancer 98:84-91
37. Macciò A, Madeddu C, Massa D, Mudu MC, Lusso MR, Gramignano G, Serpe R, Melis GB, Mantovani G (2005) Hemoglobin levels correlate with interleukin-6 levels in patients with advanced untreated epithelial ovarian cancer: role of inflammation in cancer-related anemia. Blood 106:362-367
38. Procaccini C, Jirillo E, Matarese G (2012) Leptin as an immunomodulator. Mol Aspects Med 33:35-45
39. Mantovani G, Macciò A, Mura L, Massa E, Mudu MC, Mulas C, Lusso MR, Madeddu C, Dessì A (2000) Serum levels of leptin and proinflammatory cytokines in patients with advanced-stage cancer at different sites. J Mol Med 78:554-561
40. Mantovani G, Macciò A, Madeddu C, Mura L, Massa E, Mudu MC, Mulas C, Lusso MR, Gramignano G, Piras MB (2001) Serum values of proinflammatory cytokines are inversely correlated with serum leptin levels in patients with advanced stage cancer at different sites. J Mol Med 79:406-414
41. Aleman MR, Santolaria F, Batista N, de La Vega M, Gonzalez-Reimers E, Milena A, Llanos M, Gómez-Sirvent JL (2002) Leptin role in advanced lung cancer. A mediator of the acute phase response or a marker of the status of nutrition? Cytokine 19:21-26
42. Macciò A, Madeddu C (2012) Inflammation and ovarian cancer. Cytokine 58:133-147
43. Bode JG, Albrecht U, Häussinger D, Heinrich PC, Schaper F (2012) Hepatic acute phase proteins - regulation by IL-6- and IL-1-type cytokines involving STAT3 and its crosstalk with NF-κB-dependent signaling. Eur J Cell Biol 91:496-505
44. Heinrich PC, Castell JV, Andus T (1990) Interleukin-6 and the acute phase response. Biochem J 265:621-636
45. Stone RL, Nick AM, McNeish IA, Balkwill F, Han HD, Bottsford-Miller J, Rupairmoole R, Armaiz-Pena GN, Pecot CV, Coward J et al (2012) Paraneoplastic thrombocytosis in ovarian cancer. N Engl J Med 366:610-618
46. Macciò A, Madeddu C, Gramignano G, Mulas C, Sanna E, Mantovani G (2010) Efficacy and safety of oral lactoferrin supplementation in combination with rHuEPO-beta for the treatment of anemia in advanced cancer patients undergoing chemotherapy: open-label, randomized controlled study. Oncologist 15:894-902
47. Macciò A, Madeddu C, Gramignano G, Mulas C, Floris C, Sanna E, Cau MC, Panzone F, Mantovani G (2012) A randomized phase III clinical trial of a combined treatment for cachexia in patients with gynecological cancers: evaluating the impact on metabolic and inflammatory profiles and quality of life. Gynecol Oncol 124:417-425
48. Jehn CF, Kühnhardt D, Bartholomae A, Pfeiffer S, Schmid P, Possinger K, Flath BC, Lüftner D (2010) Association of IL-6, hypothalamus-pituitary- adrenal axis function, and depression in patients with cancer. Integr Cancer Ther 9:270-275
49. Arden-Close E, Gidron Y, Moss-Morris R (2008) Psychological distress and its correlates in ovarian cancer: a systematic review. Psychooncology 17:1061-1072
50. Norton TR, Manne SL, Rubin S, Carlson J, Hernandez E, Edelson MI, Rosenblum N, Warshal D, Bergman C (2004) Prevalence and predictors of psychological distress among women with ovarian cancer. J Clin Oncol 22:919-926
51. Costanzo ES, Lutgendorf SK, Sood AK, Anderson B, Sorosky J, Lubaroff DM (2005) Psychosocial factors and interleukin-6 among women with advanced ovarian cancer. Cancer 104:305-313
52. Lutgendorf SK, Weinrib AZ, Penedo F, Russell D, DeGeest K, Costanzo ES, Henderson PJ, Sephton SE, Rohleder N, Lucci JA 3rd et al (2008) Interleukin-6, cortisol, and depressive symptoms in ovarian cancer patients. J Clin Oncol 26:4820-4827
53. Schrepf A, Clevenger L, Christensen D, Degeest K, Bender D, Ahmed A, Goodheart MJ, Dahmoush L, Penedo F, Lucci JA 3rd et al (2012) Cortisol and inflammatory processes in ovarian cancer patients following primary treatment: Relationships with depression, fatigue, and disability. Brain Behav Immun. doi: 10.1016/j.bbi.2012.07.022
54. Tisdale MJ (2009) Mechanisms of cancer cachexia. Physiol Rev 89:381-410
55. Semaan A, Munkarah AR, Arabi H, Bandyopadhyay S, Seward S, Kumar S, Qazi A, Hussein Y, Morris RT, Ali-Fehmi R (2011) Expression of GLUT-1 in epithelial ovarian carcinoma: correlation with tumor cell proliferation, angiogenesis, survival and ability to predict optimal cytoreduction. Gynecol Oncol 121:181-186
56. Gerriets VA, Rathmell JC (2012) Metabolic pathways in T cell fate and function. Trends Immunol 33:168-173
57. Mazurek S (2011) Pyruvate kinase type M2: a key regulator of the metaolic budget system in tumor cells. Int J Biochem Cell Biol 43:969-980
58. Semenza GL (2010) HIF-1: upstream and downstream of cancer metabolism. Curr Opin Genet Dev 20:51-56
59. Warburg O (1956) On the origin of cancer cells. Science 123:309-314
60. Gatenby RA, Gillies RJ (2004) Why do cancers have high aerobic glycolysis? Nat Rev Cancer 4:891-989
61. Bongaerts GP, van Halteren HK, Verhagen CA, Wagener DJ (2006) Cancer cachexia demonstrates the energetic impact of gluconeogenesis in human metabolism. Med Hypotheses 67:1213-1222
62. Lundholm K, Edström S, Karlberg I, Ekman L, Scherstén T (1982) Glucose turnover, gluconeogenesis from glycerol, and estimation of net glucose cycling in cancer patients. Cancer 50:1142-1150
63. Eden E, Edstrom S, Bennegard K, Schersten T, Lundholm K (1984) Glucose flux in relation to energy expenditure in malnourished patients with and without cancer during periods of fasting and feeding. Cancer Res 44:1718-1724
64. Carson JA, Baltgalvis KA (2010) Interleukin 6 as a key regulator of muscle mass during cachexia. Exerc Sport Sci Rev 38:168-176
65. Zhong Z, Wen Z, Darnell JE (1994) Stat3: a STAT family member activated by tyrosine phosphorylation in response to epidermal growth factor and interleukin-6. Science 264:95-98
66. Demaria M, Giorgi C, Lebiedzinska M, Esposito G, D'Angeli L, Bartoli A, Gough DJ, Turkson J, Levy DE, Watson CJ et al (2010) A STAT3-mediated metabolic switch is involved in tumour transformation and STAT3 addiction. Aging 2:823-842
67. Tomiyama A, Serizawa S, Tachibana K, Sakurada K, Samejima H, Kuchino Y, Kitanaka C (2006) Critical role for mitochondrial oxidative phosphorylation in the activation of tumor suppressors Bax and Bak. J Natl Cancer Inst 98:1462-1473
68. Wong JY, Huggins GS, Debidda M, Munshi NC, De Vivo I (2008) Dichloroacetate induces apoptosis in endometrial cancer cells. Gynecol Oncol 109:394-402
69. Michelakis ED, Webster L, Mackey JR (2008) Dichloroacetate (DCA) as a potential metabolic-targeting therapy for cancer. Br J Cancer 99:989-994
70. Feuerecker B, Pirsig S, Seidl C, Aichler M, Feuchtinger A, Bruchelt G, Senekowitsch-Schmidtke R (2012) Lipoic acid inhibits cell proliferation of tumor cells in vitro and in vivo. Cancer Biol Ther 13:1425-1435
71. Blumberg D, Hochwald S, Brennan MF, Burt M (1995) Interleukin-6 stimulates gluconeogenesis in primary cultures of rat hepatocytes. Metabolism 44:145-146
72. Lundholm K, Edström S, Ekman L, Karlberg I, Scherstén T (1981) Metabolism in peripheral tissues in cancer patients. Cancer Treat Rep 65(Suppl 5):79-83
73. Argilés JM, López-Soriano FJ (1999) The role of cytokines in cancer cachexia. Med Res Rev 19:223-248
74. Kim TH, Choi SE, Ha ES, Jung JG, Han SJ, Kim HJ, Kim DJ, Kang Y, Lee KW (2011) IL-6 induction of TLR-4 gene expression via STAT3 has an effect on insulin resistance in human skeletal muscle. Acta Diabetol. doi: 10.1007/s00592-011-0259-z
75. Bonetto A, Aydogdu T, Jin X, Zhang Z, Zhan R, Puzis L, Koniaris LG, Zimmers TA (2012) JAK/STAT3 pathway inhibition blocks skeletal muscle wasting downstream of IL-6 and in experimental cancer cachexia. Am J Physiol Endocrinol Metab 303:E410-E421
76. Gercel-Taylor C, Doering DL, Kraemer FB, Taylor DD (1996) Aberrations in normal systemic lipid metabolism in ovarian cancer patients. Gynecol Oncol 60:35-41
77. Trujillo ME, Sullivan S, Harten I, Schneider SH, Greenberg AS, Fried SK (2004) Interleukin-6 regulates human adipose tissue lipid metabolism and leptin production in vitro. J Clin Endocrinol Metab 89:5577-5582
78. Patra SK, Arora S (2012) Integrative role of neuropeptides and cytokines in cancer anorexia-cachexia syndrome. Clin Chim Acta 413:1025-1034
79. Inui A (1999) Cancer anorexia-cachexia syndrome: are neuropeptides the key? Cancer Res 59:4493-4501
80. Señarís RM, Trujillo ML, Navia B, Comes G, Ferrer B, Giralt M, Hidalgo J (2011) Interleukin-6 regulates the expression of hypothalamic neuropeptides involved in body weight in a gender-dependent way. J Neuroendocrinol 23:675-686
81. Hoene M, Weigert C (2010) The stress response of the liver to physical exercise. Exerc Immunol Rev 16:163-183
82. Das UN (2006) Is pyruvate an endogenous anti-inflammatory molecule? Nutrition 22:965-972
83. Fink MP (2007) Ethyl pyruvate: a novel treatment for sepsis. Curr Drug Targets 8:515-518
84. Wen H, Ting JP, O'Neill LA (2012) A role for the NLRP3 inflammasome in metabolic diseases - did Warburg miss inflammation? Nat Immunol 13:352-357
85. Yoon S, Woo SU, Kang JH, Kim K, Kwon MH, Park S, Shin HJ, Gwak HS, Chwae YJ (2010) STAT3 transcriptional factor activated by reactive oxygen species induces IL-6 in starvation-induced autophagy of cancer cells. Autophagy 6:1125-1138
86. Goossens GH, Blaak EE, Theunissen R, Duijvestijn AM, Clément K, Tervaert JW, Thewissen MM (2012) Expression of NLRP3 inflammasome and T cell population markers in adipose tissue are associated with insulin resistance and impaired glucose metabolism in humans. Mol Immunol 50:142-149
87. Lee MJ, Fried SK (2009) Integration of hormonal and nutrient signals that regulate leptin synthesis and secretion. Am J Physiol Endocrinol Metab 296:E1230-E1238
88. Morris DL, Rui L (2009) Recent advances in understanding leptin signaling and leptin resistance. Am J Physiol Endocrinol Metab 297:E1247-E1259
89. Levy JR, Stevens W (2001) The effects of insulin, glucose, and pyruvate on the kinetics of leptin secretion. Endocrinology 142:3558-3562
90. Cammisotto PG, Gélinas Y, Deshaies Y, Bukowiecki LJ (2005) Regulation of leptin secretion from white adipocytes by insulin, glycolytic substrates, and amino acids. Am J Physiol Endocrinol Metab 289:E166-E171
91. Visintin I, Feng Z, Longton G, Ward DC, Alvero AB, Lai Y, Tenthorey J, Leiser A, Flores-Saaib R, Yu H et al (2008) Diagnostic markers for early detection of ovarian cancer. Clin Cancer Res 14:1065-1072
92. Mor G, Visintin I, Lai Y, Zhao H, Schwartz P, Rutherford T, Yue L, Bray-Ward P, Ward DC (2005) Serum protein markers for early detection of ovarian cancer. Proc Natl Acad Sci U S A 102:7677-7682
93. Matte I, Lane D, Laplante C, Rancourt C, Piché A (2012) Profiling of cytokines in human epithelial ovarian cancer ascites. Am J Cancer Res 2:566-580
94. Hwang J, Na S, Lee H, Lee D (2009) Correlation between preoperative serum levels of five biomarkers and relationships between these biomarkers and cancer stage in epithelial ovarian cancer. J Gynecol Oncol 20:169-175
95. Preston CC, Goode EL, Hartmann LC, Kalli KR, Knutson KL (2011) Immunity and immune suppression in human ovarian cancer. Immunotherapy 3:539-556
96. Yigit R, Massuger LF, Figdor CG, Torensma R (2010) Ovarian cancer creates a suppressive microenvironment to escape immune elimination. Gynecol Oncol 117:366-372
97. Gavalas NG, Karadimou A, Dimopoulos MA, Bamias A (2010) Immune response in ovarian cancer: how is the immune system involved in prognosis and therapy: potential for treatment utilization. Clin Dev Immunol 2010:791603
98. Kusuda T, Shigemasa K, Arihiro K, Fujii T, Nagai N, Ohama K (2005) Relative expression levels of Th1 and Th2 cytokine mRNA are independent prognostic factors in patients with ovarian cancer. Oncol Rep 13:1153-1158
99. Vermeij R, de Bock GH, Leffers N, Ten Hoor KA, Schulze U, Hollema H, van der Burg SH, van der Zee AG, Daemen T, Nijman HW (2011) Tumor-infiltrating cytotoxic T lymphocytes as independent prognostic factor in epithelial ovarian cancer with wilms tumor protein 1 overexpression. J Immunother 34:516-523
100. Tomsová M, Melichar B, Sedláková I, Steiner I (2008) Prognostic significance of CD3+ tumor-infiltrating lymphocytes in ovarian carcinoma. Gynecol Oncol 108:415-420
101. Mantovani G, Macciò A, Pisano M, Versace R, Lai P, Esu S, Massa E, Ghiani M, Dessì D, Melis GB et al (1997) Tumor-associated lympho-monocytes from neoplastic effusions are immunologically defective in comparison with patient autologous PBMCs but are capable of releasing high amounts of various cytokines. Int J Cancer 71:724-731
102. Lai P, Rabinowich H, Crowley-Nowick PA, Bell MC, Mantovani G, Whiteside TL (1996) Alterations in expression and function of signal-transducing proteins in tumor-associated T and natural killer cells in patients with ovarian carcinoma. Clin Cancer Res 2:161-173
103. Giuntoli RL 2nd, Webb TJ, Zoso A, Rogers O, Diaz-Montes TP, Bristow RE, Oelke M (2009) Ovarian cancer-associated ascites demonstrates altered immune environment: implications for antitumor immunity. Anticancer Res 29:2875-2884
104. Jeannin P, Duluc D, Delneste Y (2011) IL-6 and leukemia-inhibitory factor are involved in the generation of tumor-associated macrophage: regulation by IFN-c. Immunotherapy 3:23-26
105. Duluc D, Delneste Y, Tan F, Moles MP, Grimaud L, Lenoir J, Preisser L, Anegon I, Catala L, Ifrah N et al (2007) Tumor-associated leukemia inhibitory factor and IL-6 skew monocyte differentiation into tumor-associated macrophage-like cells. Blood 110:4319-4330
106. Robinson-Smith TM, Isaacsohn I, Mercer CA, Zhou M, Van Rooijen N, Husseinzadeh N (2007) Macrophages mediate inflammation-enhanced metastasis of ovarian tumors in mice. Cancer Res 67:5708-5716
107. Hagemann T, Wilson J, Kulbe H, Li NF, Leinster DA, Charles K, Klemm F, Pukrop T, Binder C, Balkwill FR (2005) Macrophages induce invasiveness of epithelial cancer cells via NF-kappa B and JNK. J Immunol 175:1197-1205
108. Nowak M, Klink M, Glowacka E, Sulowska Z, Kulig A, Szpakowski M, Szyllo K, Tchorzewski H (2010) Production of cytokines during interaction of peripheral blood mononuclear cells with autologous ovarian cancer cells or benign ovarian tumour cells. Scand J Immunol 71:91-98
109. Wang H, Xie X, Lu WG, Ye DF, Chen HZ, Li X, Cheng Q (2004) Ovarian carcinoma cells inhibit T cell proliferation: suppression of IL-2 receptor beta and gamma expression and their JAK-STAT signaling pathway. Life Sci 74:1739-1749
110. Tormo AJ, Letellier MC, Sharma M, Elson G, Crabé S, Gauchat JF (2012) IL-6 activates STAT5 in T cells. Cytokine 60:575-562
111. Tanaka M, Suganami T, Kim-Saijo M, Toda C, Tsuiji M, Ochi K, Kamei Y, Minokoshi Y, Ogawa Y (2011) Role of central leptin signaling in the starvation-induced alteration of B-cell development. J Neurosci 31:8373-8380
112. Matarese G, Sanna V, Fontana S, Zappacosta S (2002) Leptin as a novel therapeutic target for immune intervention. Curr Drug Targets Inflamm Allergy 1:13-22
113. Tschöp J, Nogueiras R, Haas-Lockie S, Kasten KR, Castañeda TR, Huber N, Guanciale K, Perez-Tilve D, Habegger K, Ottaway N et al (2010) CNS leptin action modulates immune response and survival in sepsis. J Neurosci 30:6036-6047
114. Obermair A, Handisurya A, Kaider A, Sevelda P, Kölbl H, Gitsch G (1998) The relationship of pretreatment serum hemoglobin level to the survival of epithelial ovarian carcinoma patients: a prospective review. Cancer 83:726-723
115. Macciò A, Madeddu C (2012) Management of anemia of inflammation in the elderly. Anemia 2012:563251
116. Kim JH, Lee JM, Ryu KS, Lee YS, Park YG, Hur SY, Lee KH, Lee SH (2011) The prognostic impact of duration of anemia during chemotherapy in advanced epithelial ovarian cancer. Oncologist 16:1154-1161
117. Spivak JL (2000) The blood in systemic disorders. Lancet 355:1707-1712
118. Morceau F, Dicato M, Diederich M (2009) Pro-inflammatory cytokine-mediated anemia: regarding molecular mechanisms of erythropoiesis. Mediat Inflamm 2009:405016
119. Andrews NC (2004) Anemia of inflammation: the cytokine-hepcidin link. J Clin Invest 113:1251-1253
120. Wrighting DM, Andrews NC (2006) Interleukin-6 induces hepcidin expression through STAT3. Blood 108:3204-3209
121. Neumcke I, Schneider B, Fandrey J, Pagel H (1999) Effects of pro- and antioxidative compounds on renal production of erythropoietin. Endocrinology 140:641-645
122. Schrijvers D, De Samblanx H, Roila F; ESMO Guidelines Working Group (2010) Erythropoiesis-stimulating agents in the treatment of anaemia in cancer patients: ESMO Clinical Practice Guidelines for use. Ann Oncol 21:v244-v247
123. Aapro M, Österborg A, Gascón P, Ludwig H, Beguin Y (2012) Prevalence and management of cancer-related anaemia, iron deficiency and the specific role of i.v. iron. Ann Oncol 23:1954-1962